Anaphylactoid reactions. As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to meloxicam. Movalis should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. Emergency help should be sought in cases where an anaphylactoid reaction occurs. If your doctor tells you to stop taking it, or your tablets have passed their expiry date, ask your pharmacist what to do with any that are left over. Product description What it looks like

All medicines have benefits and risks. Your doctor has weighed the risks of you taking MOVALIS against the benefits they expect it will have for you. Colestiramina leagă meloxicamul la nivelul tractului gastrointestinal, accelerând astfel eliminarea meloxicamului.Chemical names: 4-hydroxy-2-methyl -N-(5-methyl-2- thiazolyl)-2 H-1,2-benzothiazine-3- carboxamide-1,1-dioxide and 2 H-1,2-benzothiazine-3- carboxamide, 4-hydroxy-2-methy -N-(5-methyl-2-thiazolyl)-1,1-dioxide. Molecular formula: C 14H 13N 3O 4S 2. MW: 351.4. CAS: 71125-38-7. Meloxicam is a pastel yellow solid with pKa values of 1.09 and 4.18 and a melting point of about 256°C. The substance is practically insoluble in water, soluble in dimethylformamide, slightly soluble in chloroform and acetone and very slightly soluble in methanol. There are no chiral centres and no polymorphs are formed under normal conditions.

Pemetrexed. For the concomitant use of meloxicam with pemetrexed in patients with creatinine clearance from 45 to 79 mL/min, the administration of meloxicam should be paused for 5 days before, on the day of, and 2 days following pemetrexed administration. If a combination of meloxicam with pemetrexed is necessary, patients should be closely monitored, especially for myelosuppression and gastrointestinal adverse reactions. In patients with creatinine clearance below 45 mL/min the concomitant administration of meloxicam with pemetrexed is not recommended. Concomitant administration of a potentially myelotoxic drug, in particular methotrexate, appears to be a predisposing factor to the onset of a cytopenia. In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg (half a 15 mg tablet) per day. These medicines may be affected by MOVALIS or may affect how well it works. You may need different amounts of your medicines, or you may need different medicines. alte AINS, inclusiv salicilaţi în doze mari (acid acetilsalicilic): administrarea concomitentă câtorva AINS poate creşte riscul ulceraţiilor şi al sângerărilor gastrointestinale prin efect sinergic. Utilizarea meloxicamului asociat altor AINS nu este recomandată.If you have trouble remembering to take your medicine, ask your pharmacist for some hints. How long to take it for

The maximum recommended daily dose of Movalis is 15 mg. A dose of 15 mg/day should not be exceeded. As a dose for children has not been established, use should be restricted to adults (see Precautions, Paediatric use). If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous. Side effects Litiu: AINS cresc concentraţiile plasmatice de litiu (prin scăderea excreţiei renale a litiului), care poate atinge valori toxice. Nu se recomandă administrarea concomitentă de litiu şi AINS. Dacă este necesară această asociere trebuie monitorizată cu atenţie concentratia litiului plasmatic atunci când se iniţiază, se modifică sau se întrerupe tratamentul cu meloxicam. methotrexate, a medicine used to treat rheumatoid arthritis (a painful joint disease) and some types of cancer Digoxin. Meloxicam 15 mg once daily for seven days did not alter the plasma concentration profile of digoxin after β-acetyldigoxin administration for seven days at clinical doses. In vitro testing found no protein binding drug interaction between digoxin and meloxicam.apariţia crizei de astm la anumite persoane după administrarea de aspirină sau alte AINS, inclusiv Movalis. collapse or fainting, shortness of breath or tiredness, fast or irregular heartbeat (also called palpitations), chest pain, swollen or sore leg veins Your doctor may have prescribed MOVALIS for another reason. Ask your doctor if you have any questions about why MOVALIS has been prescribed for you. Before you take it When you must not take it Metabolism. Meloxicam is eliminated almost entirely by hepatic metabolism: two-thirds by cytochrome (CYP) P450 enzymes (CYP2C9 two-thirds and CYP3A4 one-third) and one-third by other pathways, such as peroxidase oxidation. Meloxicam is almost completely metabolised to four pharmacologically inactive metabolites. The major metabolite, 5'-carboxymeloxicam (60% of dose), from CYP2C9 mediated metabolism, is formed by oxidation of an intermediate metabolite 5'-hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP3A4 isoenzyme. The patient's peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose respectively.